The possible link between pioglitazone exposure and the risk of bladder cancer has been contentious for a number of years. ABCD has now responded to the recent BMJ paper on the use of pioglitazone and bladder cancer risk. The emergence of recent evidence provides reassurance when pioglitazone safety is considered and ABCD calls for NICE to review this evidence to inform their advice on bladder cancer risk. For the ABCD response see: HERE
Date of Announcement:
Image: Dr. Alison Gallagher
Consultant Physician and Diabetologist
